Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
Sae-Il MurtadaNicole MikushMo WangPengwei RenYuki KawamuraAbhay B RamachandraDavid S LiDemetrios T BraddockGeorge TellidesLeslie B GordonJay D HumphreyPublished in: eLife (2023)
Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends the lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae. The US Food and Drug Administration approved Zokinvy (lonafarnib) in November 2020 for treating these patients, yet a detailed examination of drug-associated effects on cardiovascular structure, properties, and function has remained wanting. In this paper, we report encouraging outcomes of daily post-weaning treatment with lonafarnib on the composition and biomechanical phenotype of elastic and muscular arteries as well as associated cardiac function in a well-accepted mouse model of progeria that exhibits severe perimorbid cardiovascular disease. Lonafarnib resulted in 100% survival of the treated progeria mice to the study end-point (time of 50% survival of untreated mice), with associated improvements in arterial structure and function working together to significantly reduce pulse wave velocity and improve left ventricular diastolic function. By contrast, neither treatment with the mTOR inhibitor rapamycin alone nor dual treatment with lonafarnib plus rapamycin improved outcomes over that achieved with lonafarnib monotherapy.
Keyphrases
- mouse model
- end stage renal disease
- ejection fraction
- left ventricular
- cardiovascular disease
- clinical trial
- newly diagnosed
- chronic kidney disease
- blood pressure
- combination therapy
- prognostic factors
- peritoneal dialysis
- heart failure
- magnetic resonance
- magnetic resonance imaging
- aortic stenosis
- cell proliferation
- case report
- patient reported outcomes
- free survival
- computed tomography
- coronary artery disease
- cardiovascular risk factors
- body composition
- climate change
- cardiovascular events
- study protocol
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- left atrial
- double blind
- high fat diet induced
- cardiac resynchronization therapy